Eric Bjerkholt - Nov 30, 2022 Form 4 Insider Report for CHINOOK THERAPEUTICS, INC. (KDNY)

Role
Chief Financial Officer
Signature
/s/ Kirk Schumacher, Attorney-in-Fact
Stock symbol
KDNY
Transactions as of
Nov 30, 2022
Transactions value $
-$128,602
Form type
4
Date filed
12/2/2022, 03:25 PM
Previous filing
Jun 3, 2022
Next filing
Feb 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KDNY Common Stock Options Exercise +16.4K +73.93% 38.6K Nov 30, 2022 Direct F1
transaction KDNY Common Stock Sale -$129K -5.77K -14.94% $22.29 32.8K Dec 1, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KDNY Restricted Stock Units Options Exercise $0 -16.4K -50% $0.00 16.4K Nov 30, 2022 Common Stock 16.4K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units ("RSU") convert into common stock on a one-for-one basis.
F2 Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F3 Each RSU represents a contingent right to receive one share of Issuer's common stock.
F4 The RSUs vested as to 33.33% of the total shares on November 30, 2021 and November 30, 2022, and thereafter vests as to 33.33% of the total RSUs on November 30, 2023, subject to the provision of services to the Company on each vesting date.